News | September 02, 2014

Rivaroxaban May Be Alternative to Vitamin K Antagonists in Treating AF Patients


September 2, 2014 – Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced results from the X-VeRT trial, demonstrating once-daily rivaroxaban (Xarelto) may be an alternative to vitamin K antagonists (VKA) in treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) patients undergoing elective cardioversion, a common medical procedure to reset the heartbeat back to a regular rhythm. 
 
Cardioversion requires stable anticoagulation to help prevent life-threatening blood clots before, during and after the procedure. The X-VeRT trial is the first prospective study of any Factor Xa inhibitor in this high-risk patient population. 
 
In this 1,504 patient Phase 3b exploratory trial, compared to VKA therapies such as warfarin, 0.51 percent of patients treated with rivaroxaban were observed to have a primary efficacy outcome of stroke, transient ischemic attack, peripheral embolism, myocardial infarction or cardiovascular death compared with 1.02 percent of patients treated with VKA. In addition, 0.61 percent of patients treated with rivaroxaban were also observed to have a major bleeding event compared with 0.81 percent for VKA. The differences in both the efficacy and safety primary endpoints were not statistically significant, as this trial was not designed to determine statistical significance. 
 
Current European and American guidelines recommend at least three weeks of effective anticoagulation with a VKA (target International Normalized Ratio [INR] 2-3) prior to cardioversion and at least four weeks of anticoagulation after the procedure. 
 
"The X-VeRT study results provide physicians with additional insights that may help them manage NVAF patients who are scheduled for cardioversion," said Riccardo Cappato, M.D., Professor of Electrophysiology and Chief of Arrhythmia and Electrophysiology Center, University of Milan, Irccs Policlinico San Donato, San Donato Milanese, Milan, Italy, and co-lead investigator of the X-VeRT study. "X-VeRT explores the potential advantage of using once-daily rivaroxaban as an alternative to VKA therapy to rapidly establish and maintain stable anticoagulation and avoid delays to cardioversion." 
 
The X-VeRT study (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of cardiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) is part of the EXPLORER global cardiovascular research program for rivaroxaban. It includes 11 trials assessing the safety and efficacy of rivaroxaban in high-risk patient populations, including those with chronic heart failure, coronary artery disease, peripheral artery disease, acute coronary syndrome and embolic stroke of undetermined source. By the time of its completion, more than 275,000 patients will have participated in the XARELTO clinical development program, including completed and ongoing clinical trials, independent registries and non-interventional studies. More than 151,000 of those patients have been or will be part of controlled, randomized clinical trials. 
 
"The results of the X-VeRT study build on the promising data first seen in a post-hoc analysis of the landmark ROCKET AF trial," said Anne Hermanowski Vosatka, M.D., Ph.D., FACC, vice president and compound development team Leader for rivaroxaban, Janssen. "Xarelto is the most studied and widely prescribed Factor Xa inhibitor in the world today. We remain committed to continuing to advance our understanding of how this medicine can address critical medical needs. Beyond X-VeRT, we have initiated 10 additional studies in high-risk patient populations, including acute coronary syndrome, embolic stroke of undetermined source, and peripheral artery disease." 
 
"Patients on warfarin require significant preparation prior to having cardioversion, as they need to have their blood checked for three weeks prior to the procedure to determine if dose adjustments are needed to keep the medicine effective," said Andrea Natale, M.D., FACC, FHRS, FESC, executive medical director, Texas Cardiac Arrhythmia Institute at St. David's Medical Center. "The X-VeRT results indicate that rivaroxaban may offer a simpler process for clinicians because it does not require routine blood monitoring." 
 
For more information: www.janssenrnd.com

Related Content

News | Pharmaceuticals

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

Home January 05, 2022
Home
News | Pharmaceuticals

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...

Home January 04, 2022
Home
News | Pharmaceuticals

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

Home December 16, 2021
Home
Videos | Pharmaceuticals

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...

Home November 22, 2021
Home
News | Pharmaceuticals

November 19, 2021 — Results from two early clinical studies show the first version of an oral PCSK9-inhibitor ...

Home November 19, 2021
Home
News | Pharmaceuticals

November 15, 2021 — Esperion announced the presentation of three abstracts highlighting Nexletol tablets at the American ...

Home November 15, 2021
Home
News | Pharmaceuticals

November 15, 2021 — Novartis announced results from a pooled post-hoc analysis of Phase III ORION-9, -10 and -11 trials ...

Home November 15, 2021
Home
Feature | Pharmaceuticals | By Dave Fornell, DAIC Editor

There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...

Home October 13, 2021
Home
News | Pharmaceuticals

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

Home October 07, 2021
Home
News | Pharmaceuticals

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

Home May 15, 2021
Home
Subscribe Now